CAR - T Treatment Therapy, page-22

PTX 100 results delayed due to patients doing better than expected- ORR/PFS?
So data now due Q1 2021 - later the better.
Manufacturing more 100 - also great news.
Cap raise - now fully funded (12 months?).
Omnicar was a left field acquisition and must say I was sceptical pre presentations.
PTX is now no longer a one (two) trick pony but either could be a company maker.
Covid - bonus. Not costing us much. Could assist with dampening cytokine storm - which is a killer.
When Hopper departed from a PTX non exec director role I thought that odd but now imo it was a strategic move. The dots are becoming apparent. Hopper must have known SYC was negotiating Omnicar and recent announcement of 'Chimeric' IPO is the next phase of next generation therapeutics.
CAR-T (Chimeric) may just need the Omnicar platform
Interesting times.